A subset of breast invasive ductal carcinoma with distinctive cytomorphology, aggressive clinical behavior, and unique immunologic profiles

被引:4
作者
Lu, D [1 ]
Masood, S
Khalbuss, WE
Bui, M
机构
[1] Univ Iowa Hosp & Clin, Coll Med, Dept Pathol, Iowa City, IA 52242 USA
[2] Univ Florida, Coll Med, Hlth Sci Ctr, Dept Pathol, Jacksonville, FL USA
关键词
D O I
10.1002/cncr.10745
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Invasive ductal carcinoma of the breast is a heterogeneous collection of divergent types of carcinomas. Some subtypes have been characterized by histologic observations. This study describes a distinctive subset recognized through cytomorphologic examination of breast carcinoma specimens obtained by fine-needle aspiration biopsies (FNAB). Identification of this subset is established further by analyses of its clinical and immunologic characteristics. METHODS. One hundred patients underwent FNAB and were diagnosed with breast ductal carcinoma. These diagnoses were followed by surgical resections and histologic evaluation of tumors. Immunohistochemical analyses of estrogen receptor, progesterone receptor, Her2/neu, p53 protein, and Ki-67 were performed. Patient's age, race, and family history of breast carcinoma were obtained. The objective of the study is to identify a cytomorphologically distinctive, clinically relevant, subset of breast carcinomas. RESULTS. A subset carcinoma was recognized by cytomorphologic examination of Pap-stained FNAB slides. This subset consisted of seven patients with a median age of 37 years. At the time of surgical resection, all patients had axillary lymph node metastases. Six of seven patients had distant metastases. Immunohistochemical studies revealed that all tumors are positive for p53 protein and negative for estrogen and progesterone receptors. CONCLUSION. This study presented a unique subset of breast ductal carcinomas that involved young patients and had aggressive growth behavior. These tumors expressed p53 protein but not estrogen and progesterone receptors. (C) 2002 American Cancer Society.
引用
收藏
页码:294 / 300
页数:7
相关论文
共 41 条
[1]   Neoadjuvant therapy in breast cancer: Can we define its role? [J].
Aapro, MS .
ONCOLOGIST, 2001, 6 :36-39
[2]   APOCRINE MAMMARY-CARCINOMA - A CLINICOPATHOLOGICAL STUDY OF 72 CASES [J].
ABATI, AD ;
KIMMEL, M ;
ROSEN, PP .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 94 (04) :371-377
[3]   Histological and biological evolution of human premalignant breast disease [J].
Allred, DC ;
Mohsin, SK ;
Fuqua, SAW .
ENDOCRINE-RELATED CANCER, 2001, 8 (01) :47-61
[4]   Molecular targets for breast cancer therapy and prevention [J].
Bange, J ;
Zwick, E ;
Ullrich, A .
NATURE MEDICINE, 2001, 7 (05) :548-552
[5]   PROGNOSIS IN BREAST-CANCER UTILIZING HISTOLOGIC CHARACTERISTICS OF PRIMARY TUMOR [J].
BLACK, MM ;
BARCLAY, THC ;
HANKEY, BF .
CANCER, 1975, 36 (06) :2048-2055
[6]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[7]   Molecular profiling of breast cancer: portraits but not physiognomy [J].
Brenton, JD ;
Aparicio, SAJR ;
Caldas, C .
BREAST CANCER RESEARCH, 2001, 3 (02) :77-80
[8]   Prognostic and predictive factors in breast cancer [J].
Bundred, NJ .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :137-142
[9]  
Burke HB, 1997, CANCER, V80, P1703, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1703::AID-CNCR1>3.0.CO
[10]  
2-F